These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38574547)

  • 1. Affinity chromatography for virus-like particle manufacturing: Challenges, solutions, and perspectives.
    Ma J; Tian Z; Shi Q; Dong X; Sun Y
    J Chromatogr A; 2024 Apr; 1721():464851. PubMed ID: 38574547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles.
    Effio CL; Hubbuch J
    Biotechnol J; 2015 May; 10(5):715-27. PubMed ID: 25880158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and simulation of anion-exchange membrane chromatography for purification of Sf9 insect cell-derived virus-like particles.
    Ladd Effio C; Hahn T; Seiler J; Oelmeier SA; Asen I; Silberer C; Villain L; Hubbuch J
    J Chromatogr A; 2016 Jan; 1429():142-54. PubMed ID: 26718185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.
    Kim HJ; Lim SJ; Kwag HL; Kim HJ
    PLoS One; 2012; 7(4):e35893. PubMed ID: 22563414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platforms, advances, and technical challenges in virus-like particles-based vaccines.
    Gupta R; Arora K; Roy SS; Joseph A; Rastogi R; Arora NM; Kundu PK
    Front Immunol; 2023; 14():1123805. PubMed ID: 36845125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-derived virus-like particles as vaccines.
    Chen Q; Lai H
    Hum Vaccin Immunother; 2013 Jan; 9(1):26-49. PubMed ID: 22995837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroviral particles are effectively purified on an affinity matrix containing peptides selected by phage-display.
    Fernandes CS; Barbosa I; Castro R; Pina AS; Coroadinha AS; Barbas A; Roque AC
    Biotechnol J; 2016 Dec; 11(12):1513-1524. PubMed ID: 27491899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography.
    Ladd Effio C; Oelmeier SA; Hubbuch J
    Vaccine; 2016 Mar; 34(10):1259-67. PubMed ID: 26845741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in influenza virus-like particles bioprocesses.
    Durous L; Rosa-Calatrava M; Petiot E
    Expert Rev Vaccines; 2019 Dec; 18(12):1285-1300. PubMed ID: 31829068
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduction of Postweaning Multisystemic Wasting Syndrome-Associated Clinical Symptoms by Virus-Like Particle Vaccine Against Porcine Parvovirus and Porcine Circovirus Type 2.
    Liu G; Qiao X; Chang C; Hua T; Wang J; Tang B; Zhang D
    Viral Immunol; 2020; 33(6):444-456. PubMed ID: 32255758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downstream process design for Gag HIV-1 based virus-like particles.
    Lorenzo E; Miranda L; Gòdia F; Cervera L
    Biotechnol Bioeng; 2023 Sep; 120(9):2672-2684. PubMed ID: 37148527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer-grafted chromatography media for the purification of enveloped virus-like particles, exemplified with HIV-1 gag VLP.
    Pereira Aguilar P; Schneider TA; Wetter V; Maresch D; Ling WL; Tover A; Steppert P; Jungbauer A
    Vaccine; 2019 Nov; 37(47):7070-7080. PubMed ID: 31300289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VLP-factory™ and ADDomer
    Sari-Ak D; Bufton J; Gupta K; Garzoni F; Fitzgerald D; Schaffitzel C; Berger I
    Curr Protoc; 2021 Mar; 1(3):e55. PubMed ID: 33729713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage Qβ Coat Protein Trigger the Production of Neutralizing Antibodies.
    Guo Y; Guo R; Ma Y; Chang W; Ming S; Yang G; Guo Y
    Curr Top Med Chem; 2021 Oct; 21(14):1235-1250. PubMed ID: 34145995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
    Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
    PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
    Hankaniemi MM; Stone VM; Andrejeff T; Heinimäki S; Sioofy-Khojine AB; Marjomäki V; Hyöty H; Blazevic V; Flodström-Tullberg M; Hytönen VP; Laitinen OH
    Antiviral Res; 2019 Nov; 171():104595. PubMed ID: 31491431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioengineering virus-like particles as vaccines.
    Lua LH; Connors NK; Sainsbury F; Chuan YP; Wibowo N; Middelberg AP
    Biotechnol Bioeng; 2014 Mar; 111(3):425-40. PubMed ID: 24347238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.